Broncus Technologies, Inc.

About Broncus Technologies, Inc.

Broncus Technologies, Inc. operates as a medical technology firm focused on developing and commercializing solutions for lung diseases. Originally incorporated in California in 1997, the company is now a publicly held entity with a significant presence in both San Jose, CA, and Hangzhou, China. The company's business model revolves around the sale of its advanced medical devices and software platforms to hospitals and physicians specializing in interventional pulmonology. A key milestone was its Initial Public Offering (IPO) on the Hong Kong Stock Exchange in September 2021, which raised approximately $215 million.

The company's product suite aims to provide comprehensive solutions for the diagnosis and treatment of lung conditions, including lung cancer and emphysema. One of its foundational products is the LungPoint® Virtual Bronchoscopic Navigation (VBN) system. This platform functions as a computer-assisted, image-guided tool that allows physicians to create a detailed map and receive visual guidance through the lung's airways to precisely locate and access pulmonary nodules. Further enhancing its diagnostic capabilities, Broncus offers the FleXNeedle®, a specialized coring needle designed for peripheral sampling in hard-to-reach areas of the lungs.

Building on its navigation technology, Broncus has developed the Archimedes™ System, a total lung access platform. This system integrates nodule, vessel, and airway mapping with pathway guidance and real-time fluoroscopic imaging. A key feature of this platform is the Bronchoscopic Trans-Parenchymal Nodule Access (BTPNA) technology, which enables biopsy and therapeutic access to any location within the lung. For therapeutic interventions, the company has developed the InterVapor® system, a bronchoscopic thermal vapor ablation technology for treating emphysema, and a radiofrequency ablation system for lung cancer. Broncus reported product sales of $12.41 million for fiscal year 2023, a 32% increase from the prior year, with significant growth observed in Mainland China.